Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ANIK 
Anika Therapeutics Inc (ANIK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: ANIK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -3.21% | Avg. Invested days 59 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 159.19M USD | Price to earnings Ratio - | 1Y Target Price 21.33 |
Price to earnings Ratio - | 1Y Target Price 21.33 | ||
Volume (30-day avg) 70108 | Beta 0.65 | 52 Weeks Range 10.85 - 29.11 | Updated Date 06/19/2025 |
52 Weeks Range 10.85 - 29.11 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.75 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -48.48% | Operating Margin (TTM) -16.37% |
Management Effectiveness
Return on Assets (TTM) -1.73% | Return on Equity (TTM) -6.07% |
Valuation
Trailing PE - | Forward PE 19.12 | Enterprise Value 131255795 | Price to Sales(TTM) 1.36 |
Enterprise Value 131255795 | Price to Sales(TTM) 1.36 | ||
Enterprise Value to Revenue 1.12 | Enterprise Value to EBITDA 170.46 | Shares Outstanding 14341400 | Shares Floating 10334573 |
Shares Outstanding 14341400 | Shares Floating 10334573 | ||
Percent Insiders 4.12 | Percent Institutions 90.28 |
Analyst Ratings
Rating 4.67 | Target Price 21.33 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Anika Therapeutics Inc
Company Overview
History and Background
Anika Therapeutics Inc. was founded in 1992. It initially focused on developing and commercializing hyaluronic acid (HA)-based products for tissue repair, protection, and regeneration. Over time, it expanded its portfolio and market reach through internal development and acquisitions.
Core Business Areas
- Joint Health: Develops and commercializes HA-based products for osteoarthritis pain management, including single-injection and multi-injection viscosupplements.
- Surgical: Offers products for soft tissue repair, wound closure, and ophthalmic applications.
- Regenerative Solutions: Focuses on developing innovative therapies for tissue regeneration and repair, including cartilage regeneration and bone grafting.
Leadership and Structure
Anika Therapeutics Inc. is led by a CEO and a senior management team responsible for different functional areas like R&D, sales, marketing, and finance. The organizational structure consists of various departments and teams focused on product development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- CINGAL: A single-injection HA viscosupplement with triamcinolone acetonide for osteoarthritis pain relief. Competitors include other steroid-HA combination injections. Estimated at 10% market share in Combination products segment.
- HYALOFAST: A resorbable scaffold for cartilage regeneration. Competitors include Vericel (MACI) and other cell-based therapies.
- INTEGRA: A line of dermal regeneration products. Competitors include Aroa Biosurgery Ltd. (AROA) and Organogenesis Inc. (ORGO). Revenue data specific to INTEGRA within Anika's portfolio is not publicly disclosed.
- Monovisc: A single-injection HA viscosupplement for osteoarthritis pain relief. Competitors include Sanofi (SYNVISC, SYNVISC-ONE) and Seikagaku Corporation (GEL-ONE). Anika is estimated to have around 12% market share in single injection viscosupplements.
Market Dynamics
Industry Overview
The market for osteoarthritis pain management and regenerative medicine is growing due to the aging population and increasing prevalence of musculoskeletal disorders. Demand for minimally invasive procedures and advanced therapies is driving innovation in the industry.
Positioning
Anika Therapeutics Inc. is positioned as a specialty orthopedics and regenerative medicine company focused on developing and commercializing HA-based products and advanced therapies. Competitive advantages include its expertise in HA technology, established distribution network, and portfolio of differentiated products.
Total Addressable Market (TAM)
The total addressable market for osteoarthritis treatments and regenerative medicine is estimated to be in the billions of dollars. Anika is positioned to capture a portion of this TAM through its focus on HA-based therapies and innovation.
Upturn SWOT Analysis
Strengths
- Strong expertise in hyaluronic acid (HA) technology
- Established distribution network
- Differentiated product portfolio
- Focus on growing markets in orthopedics and regenerative medicine
- History of successful acquisitions
Weaknesses
- Reliance on HA-based products, limiting diversification
- Competition from larger players with greater resources
- Dependence on regulatory approvals for new products
- Vulnerable to commoditization in certain product categories
- Past issues with manufacturing quality control
Opportunities
- Expansion into new geographic markets
- Development of new HA-based therapies for other indications
- Strategic acquisitions of complementary technologies or products
- Partnerships with other companies to expand market reach
- Growing market for regenerative medicine products
Threats
- Increasing competition from established and emerging players
- Pricing pressure from healthcare providers and payers
- Changes in regulatory requirements
- Technological advancements that could render existing products obsolete
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- SNY
- JNJ
- ZBH
Competitive Landscape
Anika Therapeutics Inc. competes with larger companies with greater resources. Competitive advantages include its expertise in HA technology and portfolio of differentiated products. Disadvantages include its smaller size and limited resources compared to larger competitors.
Major Acquisitions
Parcus Medical, LLC
- Year: 2019
- Acquisition Price (USD millions): 26
- Strategic Rationale: To expand Anika's sports medicine product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the expansion of its product portfolio and market reach. Growth has been inconsistent, with periods of rapid expansion followed by periods of slower growth.
Future Projections: Future growth projections are based on analyst estimates for revenue and earnings growth. These estimates should be analyzed in light of the company's strategic initiatives and market trends.
Recent Initiatives: Recent strategic initiatives include new product launches, acquisitions, and partnerships aimed at expanding the company's product portfolio and market reach. Focus on regenerative medicine segment.
Summary
Anika Therapeutics is a specialty orthopedics and regenerative medicine company with a focus on HA-based therapies. Its strengths lie in its HA technology expertise and differentiated product portfolio. Anika needs to be mindful of the increasing competitive pressure and regulatory requirements. Its future growth depends on successful execution of strategic initiatives in expanding into new markets and developing new therapies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Company website
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and may vary. Financial data is based on historical information and analyst estimates, which are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anika Therapeutics Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 1993-04-29 | President, CEO & Director Dr. Cheryl Renee Blanchard Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 288 | Website https://www.anika.com |
Full time employees 288 | Website https://www.anika.com | ||
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.